Phosphate salivary secretion in hemodialysis patients

Implications for the treatment of hyperphosphatemia

Vincenzo Savica, Lorenzo A. Calò, Renato Caldarera, Adelaide Cavaleri, Antonio Granata, Domenico Santoro, Rodolfo Savica, Ugo Muraca, Agostino Mallamace, Guido Bellinghieri

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background/Aims: Hyperphosphatemia is recognized as contributing to the increased risk of cardiac death in end-stage renal disease (ESRD) and hemodialysis (HD) patients. Currently available pharmacologic treatment for hyperphosphatemia is based on phosphate binders but, despite treatment, only half of the patients fall within the range for serum phosphorus of the K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches in order to reduce serum phosphate. Salivary fluid contains phosphate which, if related to the daily salivary secretion (1,000-1,880 ml), may raise interest in order to identify further additive approaches to phosphorus removal in uremic patients, while data about salivary phosphate secretion in ESRD patients are controversial. Methods: This study evaluates salivary phosphate secretion in 68 HD patients compared with 30 healthy subjects. Saxon's test confirmed normal salivary function in patients and controls. Salivary calcium and serum phosphate, calcium and PTH were also measured. Results: HD patients had significantly higher salivary phosphorus levels compared with healthy controls: 30.35 (26.5-34.6) vs. 12.1 (10.58-14.73) mg/dl (p < 0.0001), and this significantly correlated (p < 0.0001) with serum phosphorus. Multiple regression analysis confirmed serum phosphorus as the only predictor (p < 0.0001) of salivary phosphorus. Conclusions: Given the functional secretive similarity between salivary glands and the kidneys, this increased salivary phosphate secretion might be interpreted as being compensatory in the presence of renal failure. Absorption of the increased salivary phosphate secretion, however, may worsen hyperphosphatemia; therefore, the binding of salivary phosphate might be considered as a further therapeutic approach to hyperphosphatemia in ESRD.

Original languageEnglish (US)
JournalNephron - Physiology
Volume105
Issue number3
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Hyperphosphatemia
Renal Dialysis
Phosphates
Phosphorus
Chronic Kidney Failure
Serum
Therapeutics
Salivary Glands
Renal Insufficiency
Healthy Volunteers
Regression Analysis
Guidelines
Calcium
Kidney

Keywords

  • Hyperphosphatemia
  • Phosphate, salivary

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Savica, V., Calò, L. A., Caldarera, R., Cavaleri, A., Granata, A., Santoro, D., ... Bellinghieri, G. (2007). Phosphate salivary secretion in hemodialysis patients: Implications for the treatment of hyperphosphatemia. Nephron - Physiology, 105(3). https://doi.org/10.1159/000098544

Phosphate salivary secretion in hemodialysis patients : Implications for the treatment of hyperphosphatemia. / Savica, Vincenzo; Calò, Lorenzo A.; Caldarera, Renato; Cavaleri, Adelaide; Granata, Antonio; Santoro, Domenico; Savica, Rodolfo; Muraca, Ugo; Mallamace, Agostino; Bellinghieri, Guido.

In: Nephron - Physiology, Vol. 105, No. 3, 01.02.2007.

Research output: Contribution to journalArticle

Savica, V, Calò, LA, Caldarera, R, Cavaleri, A, Granata, A, Santoro, D, Savica, R, Muraca, U, Mallamace, A & Bellinghieri, G 2007, 'Phosphate salivary secretion in hemodialysis patients: Implications for the treatment of hyperphosphatemia', Nephron - Physiology, vol. 105, no. 3. https://doi.org/10.1159/000098544
Savica, Vincenzo ; Calò, Lorenzo A. ; Caldarera, Renato ; Cavaleri, Adelaide ; Granata, Antonio ; Santoro, Domenico ; Savica, Rodolfo ; Muraca, Ugo ; Mallamace, Agostino ; Bellinghieri, Guido. / Phosphate salivary secretion in hemodialysis patients : Implications for the treatment of hyperphosphatemia. In: Nephron - Physiology. 2007 ; Vol. 105, No. 3.
@article{667421695b5c4c2c8f6b58bf7ef12016,
title = "Phosphate salivary secretion in hemodialysis patients: Implications for the treatment of hyperphosphatemia",
abstract = "Background/Aims: Hyperphosphatemia is recognized as contributing to the increased risk of cardiac death in end-stage renal disease (ESRD) and hemodialysis (HD) patients. Currently available pharmacologic treatment for hyperphosphatemia is based on phosphate binders but, despite treatment, only half of the patients fall within the range for serum phosphorus of the K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches in order to reduce serum phosphate. Salivary fluid contains phosphate which, if related to the daily salivary secretion (1,000-1,880 ml), may raise interest in order to identify further additive approaches to phosphorus removal in uremic patients, while data about salivary phosphate secretion in ESRD patients are controversial. Methods: This study evaluates salivary phosphate secretion in 68 HD patients compared with 30 healthy subjects. Saxon's test confirmed normal salivary function in patients and controls. Salivary calcium and serum phosphate, calcium and PTH were also measured. Results: HD patients had significantly higher salivary phosphorus levels compared with healthy controls: 30.35 (26.5-34.6) vs. 12.1 (10.58-14.73) mg/dl (p < 0.0001), and this significantly correlated (p < 0.0001) with serum phosphorus. Multiple regression analysis confirmed serum phosphorus as the only predictor (p < 0.0001) of salivary phosphorus. Conclusions: Given the functional secretive similarity between salivary glands and the kidneys, this increased salivary phosphate secretion might be interpreted as being compensatory in the presence of renal failure. Absorption of the increased salivary phosphate secretion, however, may worsen hyperphosphatemia; therefore, the binding of salivary phosphate might be considered as a further therapeutic approach to hyperphosphatemia in ESRD.",
keywords = "Hyperphosphatemia, Phosphate, salivary",
author = "Vincenzo Savica and Cal{\`o}, {Lorenzo A.} and Renato Caldarera and Adelaide Cavaleri and Antonio Granata and Domenico Santoro and Rodolfo Savica and Ugo Muraca and Agostino Mallamace and Guido Bellinghieri",
year = "2007",
month = "2",
day = "1",
doi = "10.1159/000098544",
language = "English (US)",
volume = "105",
journal = "Nephron - Physiology",
issn = "1660-2137",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Phosphate salivary secretion in hemodialysis patients

T2 - Implications for the treatment of hyperphosphatemia

AU - Savica, Vincenzo

AU - Calò, Lorenzo A.

AU - Caldarera, Renato

AU - Cavaleri, Adelaide

AU - Granata, Antonio

AU - Santoro, Domenico

AU - Savica, Rodolfo

AU - Muraca, Ugo

AU - Mallamace, Agostino

AU - Bellinghieri, Guido

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background/Aims: Hyperphosphatemia is recognized as contributing to the increased risk of cardiac death in end-stage renal disease (ESRD) and hemodialysis (HD) patients. Currently available pharmacologic treatment for hyperphosphatemia is based on phosphate binders but, despite treatment, only half of the patients fall within the range for serum phosphorus of the K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches in order to reduce serum phosphate. Salivary fluid contains phosphate which, if related to the daily salivary secretion (1,000-1,880 ml), may raise interest in order to identify further additive approaches to phosphorus removal in uremic patients, while data about salivary phosphate secretion in ESRD patients are controversial. Methods: This study evaluates salivary phosphate secretion in 68 HD patients compared with 30 healthy subjects. Saxon's test confirmed normal salivary function in patients and controls. Salivary calcium and serum phosphate, calcium and PTH were also measured. Results: HD patients had significantly higher salivary phosphorus levels compared with healthy controls: 30.35 (26.5-34.6) vs. 12.1 (10.58-14.73) mg/dl (p < 0.0001), and this significantly correlated (p < 0.0001) with serum phosphorus. Multiple regression analysis confirmed serum phosphorus as the only predictor (p < 0.0001) of salivary phosphorus. Conclusions: Given the functional secretive similarity between salivary glands and the kidneys, this increased salivary phosphate secretion might be interpreted as being compensatory in the presence of renal failure. Absorption of the increased salivary phosphate secretion, however, may worsen hyperphosphatemia; therefore, the binding of salivary phosphate might be considered as a further therapeutic approach to hyperphosphatemia in ESRD.

AB - Background/Aims: Hyperphosphatemia is recognized as contributing to the increased risk of cardiac death in end-stage renal disease (ESRD) and hemodialysis (HD) patients. Currently available pharmacologic treatment for hyperphosphatemia is based on phosphate binders but, despite treatment, only half of the patients fall within the range for serum phosphorus of the K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches in order to reduce serum phosphate. Salivary fluid contains phosphate which, if related to the daily salivary secretion (1,000-1,880 ml), may raise interest in order to identify further additive approaches to phosphorus removal in uremic patients, while data about salivary phosphate secretion in ESRD patients are controversial. Methods: This study evaluates salivary phosphate secretion in 68 HD patients compared with 30 healthy subjects. Saxon's test confirmed normal salivary function in patients and controls. Salivary calcium and serum phosphate, calcium and PTH were also measured. Results: HD patients had significantly higher salivary phosphorus levels compared with healthy controls: 30.35 (26.5-34.6) vs. 12.1 (10.58-14.73) mg/dl (p < 0.0001), and this significantly correlated (p < 0.0001) with serum phosphorus. Multiple regression analysis confirmed serum phosphorus as the only predictor (p < 0.0001) of salivary phosphorus. Conclusions: Given the functional secretive similarity between salivary glands and the kidneys, this increased salivary phosphate secretion might be interpreted as being compensatory in the presence of renal failure. Absorption of the increased salivary phosphate secretion, however, may worsen hyperphosphatemia; therefore, the binding of salivary phosphate might be considered as a further therapeutic approach to hyperphosphatemia in ESRD.

KW - Hyperphosphatemia

KW - Phosphate, salivary

UR - http://www.scopus.com/inward/record.url?scp=33847756383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847756383&partnerID=8YFLogxK

U2 - 10.1159/000098544

DO - 10.1159/000098544

M3 - Article

VL - 105

JO - Nephron - Physiology

JF - Nephron - Physiology

SN - 1660-2137

IS - 3

ER -